(OMCL) Omnicell - Overview
Exchange: NASDAQ •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US68213N1090
Stock: Automated Dispensing, IV Compounding, Medication Adherence, Pharmacy Analytics
Total Rating 40
Risk 90
Buy Signal -0.71
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 85.3% |
| Relative Tail Risk | -17.3% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.01 |
| Alpha | -31.35 |
| Character TTM | |
|---|---|
| Beta | 0.934 |
| Beta Downside | 1.062 |
| Drawdowns 3y | |
|---|---|
| Max DD | 67.57% |
| CAGR/Max DD | -0.18 |
Description: OMCL Omnicell January 16, 2026
Omnicell, Inc. (NASDAQ:OMCL) delivers end-to-end medication management technology to hospitals, health systems, post-acute care facilities, and retail pharmacies worldwide. Its product suite spans point-of-care dispensing robots (XT Series), central pharmacy automation, IV compounding platforms, specialty-pharmacy turnkey services, and data-driven inventory-optimization analytics, complemented by professional implementation and post-sale support.
Key performance indicators from the most recent fiscal year show revenue of roughly $1.0 billion, up about 13 % year-over-year, with an operating margin near 10 % and a backlog of $200 million that reflects strong demand for automation amid persistent nursing labor shortages. The company’s growth is further buoyed by macro trends such as the aging U.S. population, the shift toward value-based care that incentivizes medication safety, and expanding 340B program participation, all of which increase the economic value of Omnicell’s compliance and inventory-visibility solutions.
For a deeper, data-driven valuation analysis, see the ValueRay profile on OMCL.
Piotroski VR‑10 (Strict, 0-10) 7.0
| Net Income: 2.05m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.04 > 0.02 and ΔFCF/TA -2.30 > 1.0 |
| NWC/Revenue: 17.17% < 20% (prev 19.76%; Δ -2.59% < -1%) |
| CFO/TA 0.06 > 3% & CFO 127.3m > Net Income 2.05m |
| Net Debt (20.7m) to EBITDA (90.1m): 0.23 < 3 |
| Current Ratio: 1.43 > 1.5 & < 3 |
| Outstanding Shares: last quarter (45.0m) vs 12m ago -2.80% < -2% |
| Gross Margin: 42.49% > 18% (prev 0.43%; Δ 4206 % > 0.5%) |
| Asset Turnover: 57.86% > 50% (prev 52.44%; Δ 5.42% > 0%) |
| Interest Coverage Ratio: 4.64 > 6 (EBITDA TTM 90.1m / Interest Expense TTM 2.44m) |
Altman Z'' 3.09
| A: 0.10 (Total Current Assets 680.1m - Total Current Liabilities 476.6m) / Total Assets 1.97b |
| B: 0.20 (Retained Earnings 387.0m / Total Assets 1.97b) |
| C: 0.01 (EBIT TTM 11.3m / Avg Total Assets 2.05b) |
| D: 1.66 (Book Value of Equity 1.23b / Total Liabilities 742.9m) |
| Altman-Z'' Score: 3.09 = A |
Beneish M -3.17
| DSRI: 0.79 (Receivables 216.9m/256.4m, Revenue 1.18b/1.11b) |
| GMI: 1.01 (GM 42.49% / 42.75%) |
| AQI: 1.06 (AQ_t 0.58 / AQ_t-1 0.55) |
| SGI: 1.07 (Revenue 1.18b / 1.11b) |
| TATA: -0.06 (NI 2.05m - CFO 127.3m) / TA 1.97b) |
| Beneish M-Score: -3.17 (Cap -4..+1) = AA |
What is the price of OMCL shares?
As of February 09, 2026, the stock is trading at USD 37.07 with a total of 1,597,236 shares traded.
Over the past week, the price has changed by -23.88%, over one month by -26.72%, over three months by +0.71% and over the past year by -12.57%.
Over the past week, the price has changed by -23.88%, over one month by -26.72%, over three months by +0.71% and over the past year by -12.57%.
Is OMCL a buy, sell or hold?
Omnicell has received a consensus analysts rating of 3.88.
Therefore, it is recommended to buy OMCL.
- StrongBuy: 3
- Buy: 1
- Hold: 4
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the OMCL price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 57.4 | 54.9% |
| Analysts Target Price | 57.4 | 54.9% |
| ValueRay Target Price | 33.6 | -9.4% |
OMCL Fundamental Data Overview February 08, 2026
P/E Trailing = 926.75
P/E Forward = 29.4985
P/S = 1.4371
P/B = 1.3498
P/EG = 2.28
Revenue TTM = 1.18b USD
EBIT TTM = 11.3m USD
EBITDA TTM = 90.1m USD
Long Term Debt = 167.3m USD (from longTermDebt, two quarters ago)
Short Term Debt = 11.9m USD (from shortTermDebt, two quarters ago)
Debt = 217.2m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 20.7m USD (from netDebt column, last quarter)
Enterprise Value = 1.72b USD (1.70b + Debt 217.2m - CCE 196.5m)
Interest Coverage Ratio = 4.64 (Ebit TTM 11.3m / Interest Expense TTM 2.44m)
EV/FCF = 20.41x (Enterprise Value 1.72b / FCF TTM 84.5m)
FCF Yield = 4.90% (FCF TTM 84.5m / Enterprise Value 1.72b)
FCF Margin = 7.13% (FCF TTM 84.5m / Revenue TTM 1.18b)
Net Margin = 0.17% (Net Income TTM 2.05m / Revenue TTM 1.18b)
Gross Margin = 42.49% ((Revenue TTM 1.18b - Cost of Revenue TTM 681.4m) / Revenue TTM)
Gross Margin QoQ = 41.51% (prev 43.30%)
Tobins Q-Ratio = 0.87 (Enterprise Value 1.72b / Total Assets 1.97b)
Interest Expense / Debt = 0.13% (Interest Expense 284.0k / Debt 217.2m)
Taxrate = 21.0% (US default 21%)
NOPAT = 8.95m (EBIT 11.3m * (1 - 21.00%))
Current Ratio = 1.43 (Total Current Assets 680.1m / Total Current Liabilities 476.6m)
Debt / Equity = 0.18 (Debt 217.2m / totalStockholderEquity, last quarter 1.23b)
Debt / EBITDA = 0.23 (Net Debt 20.7m / EBITDA 90.1m)
Debt / FCF = 0.24 (Net Debt 20.7m / FCF TTM 84.5m)
Total Stockholder Equity = 1.24b (last 4 quarters mean from totalStockholderEquity)
RoA = 0.10% (Net Income 2.05m / Total Assets 1.97b)
RoE = 0.17% (Net Income TTM 2.05m / Total Stockholder Equity 1.24b)
RoCE = 0.80% (EBIT 11.3m / Capital Employed (Equity 1.24b + L.T.Debt 167.3m))
RoIC = 0.58% (NOPAT 8.95m / Invested Capital 1.53b)
WACC = 8.31% (E(1.70b)/V(1.92b) * Re(9.36%) + D(217.2m)/V(1.92b) * Rd(0.13%) * (1-Tc(0.21)))
Discount Rate = 9.36% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 81.65 | Cagr: 1.11%
[DCF Debug] Terminal Value 76.81% ; FCFF base≈106.4m ; Y1≈105.4m ; Y5≈109.5m
Fair Price DCF = 40.04 (EV 1.82b - Net Debt 20.7m = Equity 1.80b / Shares 44.9m; r=8.31% [WACC]; 5y FCF grow -1.72% → 2.90% )
EPS Correlation: -24.95 | EPS CAGR: -17.69% | SUE: -0.92 | # QB: 0
Revenue Correlation: -32.05 | Revenue CAGR: -0.41% | SUE: 0.13 | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.31 | Chg30d=+0.009 | Revisions Net=-1 | Analysts=8
EPS current Year (2026-12-31): EPS=1.77 | Chg30d=-0.051 | Revisions Net=+3 | Growth EPS=+9.3% | Growth Revenue=+4.7%
EPS next Year (2027-12-31): EPS=2.12 | Chg30d=-0.005 | Revisions Net=-1 | Growth EPS=+19.7% | Growth Revenue=+5.3%
P/E Forward = 29.4985
P/S = 1.4371
P/B = 1.3498
P/EG = 2.28
Revenue TTM = 1.18b USD
EBIT TTM = 11.3m USD
EBITDA TTM = 90.1m USD
Long Term Debt = 167.3m USD (from longTermDebt, two quarters ago)
Short Term Debt = 11.9m USD (from shortTermDebt, two quarters ago)
Debt = 217.2m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 20.7m USD (from netDebt column, last quarter)
Enterprise Value = 1.72b USD (1.70b + Debt 217.2m - CCE 196.5m)
Interest Coverage Ratio = 4.64 (Ebit TTM 11.3m / Interest Expense TTM 2.44m)
EV/FCF = 20.41x (Enterprise Value 1.72b / FCF TTM 84.5m)
FCF Yield = 4.90% (FCF TTM 84.5m / Enterprise Value 1.72b)
FCF Margin = 7.13% (FCF TTM 84.5m / Revenue TTM 1.18b)
Net Margin = 0.17% (Net Income TTM 2.05m / Revenue TTM 1.18b)
Gross Margin = 42.49% ((Revenue TTM 1.18b - Cost of Revenue TTM 681.4m) / Revenue TTM)
Gross Margin QoQ = 41.51% (prev 43.30%)
Tobins Q-Ratio = 0.87 (Enterprise Value 1.72b / Total Assets 1.97b)
Interest Expense / Debt = 0.13% (Interest Expense 284.0k / Debt 217.2m)
Taxrate = 21.0% (US default 21%)
NOPAT = 8.95m (EBIT 11.3m * (1 - 21.00%))
Current Ratio = 1.43 (Total Current Assets 680.1m / Total Current Liabilities 476.6m)
Debt / Equity = 0.18 (Debt 217.2m / totalStockholderEquity, last quarter 1.23b)
Debt / EBITDA = 0.23 (Net Debt 20.7m / EBITDA 90.1m)
Debt / FCF = 0.24 (Net Debt 20.7m / FCF TTM 84.5m)
Total Stockholder Equity = 1.24b (last 4 quarters mean from totalStockholderEquity)
RoA = 0.10% (Net Income 2.05m / Total Assets 1.97b)
RoE = 0.17% (Net Income TTM 2.05m / Total Stockholder Equity 1.24b)
RoCE = 0.80% (EBIT 11.3m / Capital Employed (Equity 1.24b + L.T.Debt 167.3m))
RoIC = 0.58% (NOPAT 8.95m / Invested Capital 1.53b)
WACC = 8.31% (E(1.70b)/V(1.92b) * Re(9.36%) + D(217.2m)/V(1.92b) * Rd(0.13%) * (1-Tc(0.21)))
Discount Rate = 9.36% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 81.65 | Cagr: 1.11%
[DCF Debug] Terminal Value 76.81% ; FCFF base≈106.4m ; Y1≈105.4m ; Y5≈109.5m
Fair Price DCF = 40.04 (EV 1.82b - Net Debt 20.7m = Equity 1.80b / Shares 44.9m; r=8.31% [WACC]; 5y FCF grow -1.72% → 2.90% )
EPS Correlation: -24.95 | EPS CAGR: -17.69% | SUE: -0.92 | # QB: 0
Revenue Correlation: -32.05 | Revenue CAGR: -0.41% | SUE: 0.13 | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.31 | Chg30d=+0.009 | Revisions Net=-1 | Analysts=8
EPS current Year (2026-12-31): EPS=1.77 | Chg30d=-0.051 | Revisions Net=+3 | Growth EPS=+9.3% | Growth Revenue=+4.7%
EPS next Year (2027-12-31): EPS=2.12 | Chg30d=-0.005 | Revisions Net=-1 | Growth EPS=+19.7% | Growth Revenue=+5.3%